glycine has been researched along with Rosacea in 2 studies
Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-seven adult Caucasian patients (9 males and 28 females), with erythemato-telangiectatic rosacea accompanied by stinging and burning sensation, were treated with a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan." | 7.81 | Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study. ( Barbareschi, M; De Micheli, P; Raia, DD; Schianchi, R; Veraldi, S, 2015) |
| " Rosacea is a chronic inflammatory skin disease affecting mostly facial skin." | 6.77 | Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. ( Abril, E; Berardesca, E; Caserini, M; Guglielmini, G; Iorizzo, M; Palmieri, R; Piérard, GE, 2012) |
| "Thirty-seven adult Caucasian patients (9 males and 28 females), with erythemato-telangiectatic rosacea accompanied by stinging and burning sensation, were treated with a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan." | 3.81 | Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study. ( Barbareschi, M; De Micheli, P; Raia, DD; Schianchi, R; Veraldi, S, 2015) |
| " Rosacea is a chronic inflammatory skin disease affecting mostly facial skin." | 2.77 | Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. ( Abril, E; Berardesca, E; Caserini, M; Guglielmini, G; Iorizzo, M; Palmieri, R; Piérard, GE, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Veraldi, S | 1 |
| Raia, DD | 1 |
| Schianchi, R | 1 |
| De Micheli, P | 1 |
| Barbareschi, M | 1 |
| Berardesca, E | 1 |
| Iorizzo, M | 1 |
| Abril, E | 1 |
| Guglielmini, G | 1 |
| Caserini, M | 1 |
| Palmieri, R | 1 |
| Piérard, GE | 1 |
1 trial available for glycine and Rosacea
| Article | Year |
|---|---|
Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.
Topics: Adult; Anti-Inflammatory Agents; Chi-Square Distribution; Chitosan; Dermatologic Agents; Double-Blin | 2012 |
1 other study available for glycine and Rosacea
| Article | Year |
|---|---|
Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study.
Topics: Administration, Cutaneous; Adult; Aged; Chitosan; Dermatologic Agents; Female; Glycine; Humans; Male | 2015 |